Search

Your search keyword '"D’Amato, D"' showing total 788 results
Start Over Author "D’Amato, D"
788 results on '"D’Amato, D"'

151. [Isolated mesenteric fibromatosis. A clinical case]

Author

DE TOMA, Giorgio, Plocco, M., Nicolanti, Virgilio, Cavallaro, Giuseppe, Amato, D., and Letizia, Claudio

Subjects
Adult, Male, Humans, Mesentery, Fibroma, Peritoneal Neoplasms
Abstract

The authors report a case of isolated mesenteric fibromatosis un associated with familial adenomatous polyposis or Gardner's syndrome or prior abdominal surgery. These neoplasms are usually asymptomatic until when the compression of the small or large bowel or the ureter causes symptoms; although they are benign lesions without metastases, local recurrences are very frequent. Surgical removal is the primary treatment; until now no satisfactory results have been obtained with other therapeutic modalities.

Published
1999

157. Iliac-to-isolated hepatic artery bypass in the treatment of intestinal angina: two cases

Author

Giuseppe Cavallaro, Amato D, Luca di Marzo, Antonino Cavallaro, Andrea Mingoli, and Giorgio De Toma

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Ischemia, Revascularization, Iliac Artery, Angina, Hepatic Artery, Mesenteric Vascular Occlusion, medicine, Humans, Derivation, Iliac artery, business.industry, Middle Aged, medicine.disease, Surgery, Abdominal Pain, Intestines, Radiography, medicine.anatomical_structure, Blood supply, business, Splanchnic, Cardiology and Cardiovascular Medicine, Artery
Abstract

Two cases in which a severe form of intestinal angina was cured by revascularization of an isolated hepatic artery were studied. The collateral pathways to the hepatic artery may serve, in a retrograde fashion, to assure an acceptable blood supply to the splanchnic organs, even when the disease of the 3 main vessels is so extensive that the commonly used techniques of revascularization cannot be applied. (J Vasc Surg 1998;28:1115-9.)

Published
1998

158. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience

Author

MacKenzie, J J, Amato, D, and Clarke, J T

Subjects
Adult, Canada, Gaucher Disease, Treatment Outcome, Patient Selection, Surveys and Questionnaires, Financial Support, Glucosylceramidase, Humans, Review, Practice Patterns, Physicians', Child, Drug Costs
Abstract

BACKGROUND: The management of severe Gaucher's disease was dramatically improved by the development of enzyme replacement therapy. However, this treatment is very costly (currently about $21,000 per infusion for adults at the starting dose recommended by the manufacturer). The goal of this study was to determine how enzyme replacement therapy was being prescribed and financially supported in various parts of Canada. In addition, demographic and outcome information was elicited. METHODS: Prescribing physicians were identified through professional associations and with the help of the manufacturer of the enzyme preparations used for the treatment of Gaucher's disease. The physicians were surveyed by questionnaire in July 1995. The study included all patients in Canada who had received enzyme replacement therapy for Gaucher's disease before July 1, 1995. RESULTS: A total of 25 patients (15 children and 10 adults) with type 1 Gaucher's disease, the common nonneuronopathic variant of the disease, were receiving enzyme replacement therapy by the end of 1995. The indications for treatment included massive splenomegaly, growth failure, and severe bony, hematologic and pulmonary complications of the disease; no patients with mild disease were receiving treatment. Treatment regimens varied markedly (from 12 to 160 units of enzyme/kg per month). All the patients were reported to have responded well to therapy, based on serial measurements of hematologic indices, liver and spleen volumes, and numbers of bony crises as well as patients' subjective impressions. Financial support for therapy varied markedly from one province to another. None of the reporting physicians was aware of any patients with severe Gaucher's disease who were denied therapy as a result of inability to pay for the medication. Various agencies provided financial support for therapy, including both federal and provincial governments, private insurance carriers and the commercial supplier of the enzyme. In Ontario provincial health care officials accepted the development, by a multidisciplinary panel of medical experts, of formal guidelines for determining eligibility, on the basis of objective medical criteria, for reimbursement for enzyme replacement treatment. INTERPRETATION: Although some differences were found across the country with respect to the details of treatment, the indications for enzyme replacement therapy and the selection of severely affected patients were similar in the various provinces. However, financial support was inconsistent and varied among provinces and patients. This will prove to be a challenge in future, not only with respect to this disease but also for other diseases for which effective, expensive therapy has been developed.

Published
1998

166. Genetic diseases / Molecular mechanisms

Author

Wanner, C., primary, Germain, D. P., additional, Linthorst, G., additional, Marodi, L., additional, Mauer, M., additional, Mignani, R., additional, Oliveira, J., additional, Ortiz, A., additional, Serra, A. L., additional, Svarstad, E., additional, Vujkovac, B., additional, Waldek, S., additional, Warnock, D. G., additional, West, M., additional, Schiffmann, R., additional, Mehta, A., additional, Amato, D., additional, Nair, N., additional, Zahrieh, D., additional, Huertas, P., additional, Bonatti, F., additional, Maritati, F., additional, Alberici, F., additional, Oliva, E., additional, Sinico, R. A., additional, Moroni, G., additional, Leoni, A., additional, Gregorini, G., additional, Jeannin, G., additional, Possenti, S., additional, Tumiati, B., additional, Grasselli, C., additional, Brugnano, R., additional, Salvarani, C., additional, Fraticelli, P., additional, Pavone, L., additional, Pesci, A., additional, Guida, G., additional, Neri, T. M., additional, Buzio, C., additional, Malerba, G., additional, Martorana, D., additional, Vaglio, A., additional, Oda, A., additional, Kitamura, K., additional, Mizumoto, T., additional, Eguchi, K., additional, Anzai, N., additional, Tomita, K., additional, Arsali, M., additional, Athanasiou, Y., additional, Demosthenous, P., additional, Voskarides, K., additional, Deltas, C., additional, and Pierides, A., additional

Published
2011
Full Text
View/download PDF

173. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients

Author

Paniagua, R., primary, Ventura, M.-d.-J., additional, Avila-Diaz, M., additional, Hinojosa-Heredia, H., additional, Mendez-Duran, A., additional, Cueto-Manzano, A., additional, Cisneros, A., additional, Ramos, A., additional, Madonia-Juseino, C., additional, Belio-Caro, F., additional, Garcia-Contreras, F., additional, Trinidad-Ramos, P., additional, Vazquez, R., additional, Ilabaca, B., additional, Alcantara, G., additional, and Amato, D., additional

Published
2009
Full Text
View/download PDF

179. Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis

Author

Paniagua, R., primary, Orihuela, O., additional, Ventura, M-.d.-J., additional, ávila-Díaz, M., additional, Cisneros, A., additional, Vicenté-Martínez, M., additional, Furlong, M-.d.-C., additional, García-González, Z., additional, Villanueva, D., additional, Prado-Uribe, M-.d.-C., additional, Alcántara, G., additional, and Amato, D., additional

Published
2008
Full Text
View/download PDF

191. Effectiveness, safety and feasibility of an evidence-based insulin infusion protocol targeting moderate glycaemic control in intensive cardiac care units

Author

Avanzini, Fausto, Marelli, Giuseppe, Saltafossi, Donata, Longhi, Chiara, Carbone, Stefania, Carlino, Liliana, Planca, Enrico, Vilei, Veronica, Roncaglioni, Maria Carla, Riva, Emma, Avanzini, F., Balestri, G., Bertocchi, P., Chiappa, L., Corticelli, A., Faricelli, S., Iacuitti, G., Mantovani, G., Moro, C., Mollichelli, N., Planca, E., Rogatska, R., Saltafossi, D., Schiavina, R., Tresoldi, S., Vandoni, P., Amodeo, R., Baldo, S., Bertazzolo, J., Bottan, S.L., Busi, G., Carbone, S., Carlino, L., Caspani, M., Ciceri, R., Ciotta, L., Cotza, R., D’Amato, D., Grassi, C., De Ponti, A., Di Rocco, E., Donè, V., Feliciano, F., Frigerio, I., Gagliardi, A.M., Ilardi, M., Ledda, A., Lippi, B., Longhi, C., Mamo, R.M., Mancuso, M.A., Maniscalco, G., Palazzo, E., Pellegrino, D., Pintonello, D., Pugliese, U., Radaelli, C., Stelluti, G., Stercoli, M.C., Sutera, S., Tonelli, L., Tullio, F., Battaglia, E., Maida, A., Mandolaro, D., Sala, P., Stillitano, F., Marelli, G., Vilei, V., Rumi, P., Bellato, L., Fedeli, M., Merlini, A., Pinelli, G., Colombo, E., De Luca, E., and Galimberti, C.

Abstract

Objectives: To assess the effectiveness, safety and feasibility of the revised, simplified nurse-managed version of our insulin infusion protocol, adapted to the new recommended glycaemic target of 140 to 180 mg/dL (Desio Diabetes Diagram i.v. 140–180).Methods: All clinical responses to the Desio Diabetes Diagram i.v. 140–180 in use for 3 years were recorded in patients with diabetes or hyperglycaemia admitted to our intensive cardiac care unit. To assess the feasibility, we asked nurses to complete an ad hoc questionnaire anonymously when the new insulin infusion protocol had been in use for 2 years.Results: From December 2010 to December 2013, 276 patients (173 men, median age 75 years) were treated according to the Desio Diabetes Diagram i.v. 140–180. The median time to reach glycaemic target was 4 h (Q1–Q3 2–8) in 128 patients with blood glucose >180 mg/dL and 2 h (Q1–Q3 1–4) in 82 patients with blood glucose <140 mg/dL. Once the target had been reached, insulin infusion was maintained for a median of 38 h (Q1–Q3 24–48) with blood glucose between 140 and 180 mg/dL for 58.3% of the infusion time. Over a total of 11,863 h of infusion, seven blood glucose <70 mg/dL occurred. The Desio Diabetes Diagram i.v. 140–180 protocol was considered easy to use by 93% of nurses.Conclusions: The Desio Diabetes Diagram i.v. 140–180 protocol, fully managed by nurses, with insulin and glucose intravenous infusion proved effective, safe and feasible in maintaining blood glucose between 140 and 180 mg/dL in patients with diabetes or hyperglycaemia admitted to the intensive cardiac care unit for acute cardiac events.

Published
2016
Full Text
View/download PDF

192. Long-term outcome of migraine therapy

Author

Bonuso, S., primary, Di Stasio, E., additional, Marano, E., additional, de Angelis, S., additional, Amato, D., additional, Scellini, T., additional, and Caruso, G., additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results